Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Statin therapy improves response to interferon alfa and ribavirin in chronic hepatitis C: a systematic review and meta-analysis.

Zhu Q, Li N, Han Q, Zhang P, Yang C, Zeng X, Chen Y, Lv Y, Liu X, Liu Z.

Antiviral Res. 2013 Jun;98(3):373-9. doi: 10.1016/j.antiviral.2013.04.009. Epub 2013 Apr 16. Review.

PMID:
23603497
2.

Fluvastatin as an adjuvant to pegylated interferon and ribavirin in HIV/hepatitis C virus genotype 1 co-infected patients: an open-label randomized controlled study.

Milazzo L, Caramma I, Mazzali C, Cesari M, Olivetti M, Galli M, Antinori S.

J Antimicrob Chemother. 2010 Apr;65(4):735-40. doi: 10.1093/jac/dkq002. Epub 2010 Jan 30.

3.

Pegylated interferon-α2a and ribavirin versus pegylated interferon-α2b and ribavirin in chronic hepatitis C : a meta-analysis.

Flori N, Funakoshi N, Duny Y, Valats JC, Bismuth M, Christophorou D, Daurès JP, Blanc P.

Drugs. 2013 Mar;73(3):263-77. doi: 10.1007/s40265-013-0027-1. Review.

PMID:
23436591
4.

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.

5.

An open-label randomized controlled study of pegylated interferon/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin.

Kondo C, Atsukawa M, Tsubota A, Itokawa N, Fukuda T, Matsushita Y, Kidokoro H, Kobayashi T, Narahara Y, Nakatsuka K, Kanazawa H, Sakamoto C.

J Viral Hepat. 2012 Sep;19(9):615-22. doi: 10.1111/j.1365-2893.2011.01584.x. Epub 2012 Feb 9.

PMID:
22863265
6.

A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.

Ma P, Yang JM, Hou W, Song SD, Wang L, Lu W.

Eur J Gastroenterol Hepatol. 2013 May;25(5):601-5. doi: 10.1097/MEG.0b013e32835cc899.

PMID:
23263720
8.
9.

Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.

Napoli N, Giannelli G, Parisi CV, Antonaci A, Maddalena G, Antonaci S.

New Microbiol. 2005 Jan;28(1):13-21.

PMID:
15782622
10.

Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection.

Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S.

J Hepatol. 2011 Jul;55(1):69-75. doi: 10.1016/j.jhep.2010.10.032. Epub 2010 Nov 23.

PMID:
21145856
11.

High dose daily interferon-alpha induction and secondary adjunction of ribavirin in treatment-naive patients with chronic hepatitis C. A multicentric, randomised, controlled trial.

Wartelle-Bladou C, Arpurt JP, Renou C, Pariente A, Pillon D, Nalet B, Picon M, Glibert A, Chousterman M, Grasset D, Morin T, Bernard P, Fischer D, Ramdani M, Lagier E, Rotily M; Viral Hepatitis Group of the ANGH.

Gastroenterol Clin Biol. 2006 Apr;30(4):525-32.

12.

Treatment of chronic hepatitis C in southern Taiwan.

Chuang WL, Yu ML, Dai CY, Chang WY.

Intervirology. 2006;49(1-2):99-106. Review.

PMID:
16166797
13.
14.

Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses.

Inoue Y, Hiramatsu N, Oze T, Yakushijin T, Mochizuki K, Hagiwara H, Oshita M, Mita E, Fukui H, Inada M, Tamura S, Yoshihara H, Hayashi E, Inoue A, Imai Y, Kato M, Miyagi T, Hohsui A, Ishida H, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N.

J Viral Hepat. 2010 May;17(5):336-44. doi: 10.1111/j.1365-2893.2009.01182.x. Epub 2009 Aug 12.

PMID:
19678893
15.

Efficacy of pegylated interferon alfa-2a or alfa-2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b.

Mach TH, Cieśla A, Warunek W, Janas-Skulina U, Cibor D, Owczarek D, Ciećko-Michalska I.

Pol Arch Med Wewn. 2011 Dec;121(12):434-9.

16.

Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy.

Derbala MF, El Dweik NZ, Al Kaabi SR, Al-Marri AD, Pasic F, Bener AB, Shebl FM, Amer AM, Butt MT, Yakoob R, John A, Al Mohanadi M, Al Khinji MA.

J Viral Hepat. 2008 Aug;15(8):591-9. doi: 10.1111/j.1365-2893.2008.00988.x. Epub 2008 May 14.

PMID:
18482284
17.

A randomized trial of 48 versus 24 weeks of combination pegylated interferon and ribavirin therapy in genotype 6 chronic hepatitis C.

Thu Thuy PT, Bunchorntavakul C, Tan Dat H, Rajender Reddy K.

J Hepatol. 2012 May;56(5):1012-8. doi: 10.1016/j.jhep.2011.12.020. Epub 2012 Jan 17.

PMID:
22266603
18.

Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin.

Bonardi R, Tabone M, Manca A, Pellicano R, Ciancio A, Rizzetto M.

Biomed Pharmacother. 2011 Jul;65(4):303-6. doi: 10.1016/j.biopha.2011.03.004. Epub 2011 May 30.

PMID:
21723079
19.

Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis.

Druyts E, Thorlund K, Wu P, Kanters S, Yaya S, Cooper CL, Mills EJ.

Clin Infect Dis. 2013 Apr;56(7):961-7. doi: 10.1093/cid/cis1031. Epub 2012 Dec 12. Review.

20.

Rapid, early and sustained virological responses in a cohort of Irish patients treated with pegylated interferon and ribavirin for chronic hepatitis C virus infection.

Sarwar S, Ryan EJ, Iqbal M, McCormick PA, O'Farrelly C, Hegarty J.

Ir J Med Sci. 2012 Mar;181(1):53-8. doi: 10.1007/s11845-011-0775-4. Epub 2011 Oct 29.

PMID:
22038749
Items per page

Supplemental Content

Write to the Help Desk